Imidazo[1,2-b]pyrimido[4,5-d]pyridazin-5(6H)-ones and the use thereof

US11345710B2 · kind B2 · utility

Assignee

• IMPACT THERAPEUTICS (SHANGHAI), INC · CN

Inventors

• Suixiong Cai · 安丰镇, CN
• Ye Tian · Bloomington, US
• Zhiqiang DONG · Longbeilingcun, CN
• Xiaozhu WANG · 安丰镇, CN

Key dates

• Filing date: Jul 10, 2018
• Grant date: May 31, 2022
• Expiry date: Aug 2, 2038

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K45/06
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed are imidazo[1,2-b]pyrimido[4,5-d]pyridazin-5(6H)-one compounds, specifically represented by the Formula I: or a pharmaceutically acceptable salt or prodrug thereof, wherein A and R1-R5 are defined herein. Compounds having Formula I are Wee1 kinase inhibitors. Therefore, compounds of the disclosure may be used to treat diseases caused by abnormal Wee1 activity.